<DOC>
	<DOCNO>NCT01757769</DOCNO>
	<brief_summary>The purpose study confirm large population Europe effectiveness safety observe silodosin previous clinical trial .</brief_summary>
	<brief_title>Effectiveness Safety Silodosin Treatment Benign Prostatic Hyperplasia</brief_title>
	<detailed_description>The objective study confirm large less select population ( `` real life condition '' ) positive risk-benefit balance observe silodosin double-blind , randomise clinical trial . The following aspect evaluate : - effect low urinary tract symptom ( LUTS ) , mean International Prostate Symptoms Score ( IPSS ) questionnaire - effect frequent bothersome symptom , mean International Continence Society ( ICS ) -male questionnaire - effect Quality Life ( QoL ) due urinary symptom - safety profile - adherence therapy - patient satisfaction treatment The effectiveness safety drug investigate also different subgroup subject accord age , severity disease , concomitant disease medication .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<criteria>Clinical diagnosis Benign Prostatic Hyperplasia ( BPH ) urologist ; Male subject age 60 year old ; IPSS total score equal 12 Visit 1 ( Screening ) 2 ( Baseline ) ; Able comply protocol procedure ; Written inform consent obtain begin investigational procedure . Hypersensitivity active substance excipients ; Patients cataract surgery schedule ; History orthostatic hypotension syncope ; Moderate severe renal impairment ( CLCR &lt; 50 ml/min , estimate Cockcroft Gault formula ) ; Severe hepatic impairment ; Concomitant use Î±adrenoreceptor antagonist natural/herbal product know effect LUTS ( e.g . saw palmetto serenoa serrulate/repens ) . Patients already treatment drug may enrol 4 week washout period Visit 2 ( baseline ) ; Concomitant use potent cytochrome P450 3A4 inhibitor , ketoconazole , itraconazole ritonavir ( possible pharmacokinetic interaction ) ; Prostate cancer ; History prostate bladder neck surgery , include transurethral prostatectomy , TUNA , laser minimally invasive therapy ; Active urinary tract infection ; Acute recurrent prostatitis ( 3 time last year ) ; History neurological disease may affect bladder function ; Unstable cardiovascular cerebrovascular disease ( include acute myocardial infarction , unstable angina pectoris , bypass , percutaneous transluminal coronary angioplasty , congestive heart failure class IIIIV , stroke , transient ischemic attack episode cardiac arrhythmia require treatment last 6 month ) ; History current evidence drug alcohol abuse within last 12 month ; Participation study involve administration investigational compound within past 30 day ; Any condition , investigator 's judgement , render subject unable complete study increase risk subject prevents optimal participation achieve objective study .</criteria>
	<gender>Male</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Lower urinary tract symptom</keyword>
	<keyword>benign prostatic hyperplasia</keyword>
</DOC>